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Abstract
Background: All-trans retinoic acid (atRA) plays an essential role in the regulation of gene expression, cell growth and
differentiation and is also important for normal cardiovascular development but may in turn be involved in cardiovascular
diseases, i.e. atherosclerosis and restenosis. The cellular atRA levels are under strict control involving several cytochromes
P450 isoforms (CYPs). CYP26 may be the most important regulator of atRA catabolism in vascular cells. The present study
describes the molecular cloning, characterization and function of atRA-induced expression of a spliced variant of the
CYP26B1 gene.
Methodology/Principal Findings: The coding region of the spliced CYP26B1 lacking exon 2 was amplified from cDNA
synthesized from atRA-treated human aortic smooth muscle cells and sequenced. Both the spliced variant and full length
CYP26B1 was found to be expressed in cultured human endothelial and smooth muscle cells, and in normal and
atherosclerotic vessel. atRA induced both variants of CYP26B1 in cultured vascular cells. Furthermore, the levels of spliced
mRNA transcript were 4.5 times higher in the atherosclerotic lesion compared to normal arteries and the expression in the
lesions was increased 20-fold upon atRA treatment. The spliced CYP26B1 still has the capability to degrade atRA, but at an
initial rate one-third that of the corresponding full length enzyme. Transfection of COS-1 and THP-1 cells with the CYP26B1
spliced variant indicated either an increase or a decrease in the catabolism of atRA, probably depending on the expression
of other atRA catabolizing enzymes in the cells.
Conclusions/Significance: Vascular cells express the spliced variant of CYP26B1 lacking exon 2 and it is also increased in
atherosclerotic lesions. The spliced variant displays a slower and reduced degradation of atRA as compared to the full-
length enzyme. Further studies are needed, however, to clarify the substrate specificity and role of the CYP26B1 splice
variant in health and disease.
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Introduction
Retinoids are important for normal cardiovascular development
[1] but may also be involved in cardiovascular diseases, i.e.
atherosclerosis and restenosis [2–4]. Especially the ability of
retinoids to reduce inflammation and proliferation could be of
importance for the development of cardiovascular diseases.
Biologically active retinoid metabolites are synthesized in target
cells from all-trans retinol (atROH) taken up from the circulation
[5]. There are several microsomal CYP enzymes which are
suggested to be involved in retinoid metabolism, e.g. CYP1A1,
CYP4A11, CYP3A4/5/7 and CYP2C8/9 [6,7]. Most important,
however, seems to be the CYP26, which is responsible for
catabolism of retinoic acid. It regulates intracellular levels of atRA
and degrades it into inactive derivatives or polar metabolites such
as 4-OH-RA, 4-oxo-RA, 5, 8-epoxy-RA and 18-OH-RA [8–11].
CYP26 recognizes atRA as its substrate and its expression and/or
its activity can be induced by RA both in vitro and in vivo [10,12–
14]. Three isoforms of CYP26 exist in humans: CYP26A1,
CYP26B1 and CYP26C1 [8,10,15,16]. CYP26B1 converts all-
trans-RA (atRA) to different polar metabolites with a higher
efficiency than CYP26A1 [8]. Studies on substrate specificity show
that CYP26A1 and B1 are specific for atRA, whereas CYP26C1
efficiently metabolizes both atRA and its isomer 9-cis-RA [8,15].
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phenomenon of RA-resistance has often been reported [17]. This
is probably due to retinoid-induced CYP26 expression resulting in
accelerated catabolism of atRA [18–20]. Inhibition of CYP26
activity by RA metabolism blocking agents (RAMBAs) increases
both plasma and tissue levels of atRA and generates retinoid-like
effects [8,20]. Furthermore, it has been demonstrated that
embryos from CYP26-deficient mice exhibit abnormalities that
mimic atRA-induced teratogenicity [21–23]. Some of the observed
abnormalities, however, could also be the result of a deficiency in
CYP26-generated metabolites that have active biological roles in
vivo [21].
CYP26B1 is highly expressed in intimal smooth muscle cells and
up-regulated by lower atRA levels than CYP26A1 [24]. Inhibition
of CYP26B1 by R115866 (a synthetic CYP26-inhibitor) increases
the levels of atRA in smooth muscle cells [24]. With increased
levels of endogenous atRA, a number of retinoid responsive genes
are induced, suggesting that CYP26B1 may be a key enzyme in
the regulation of retinoid levels in the vessel wall (25). CYP26B1
was shown to be the major CYP26 expressed and induced by
atRA and it is believed to be an important regulator of atRA levels
in human vascular cells [24,25]. We have recently found increased
levels of CYP26B1 in atherosclerotic lesions, with the strongest
expression found in macrophage-rich, inflammatory areas of the
lesions [4]. This localization coincides with the site where it is
likely to exert the strongest effect on atRA levels and on the extent
of inflammation in the lesion. The CYP26B1 gene consists of six
exons and a large second intron of 8.57 kb and covers about
18,000 base pairs (bp) [26]. The gene also has a 3 kb long
untranslated 3’ region. So far, no spliced variants of CYP26B1 have
been reported.
In this study we describe the cloning and functional studies of an
atRA-induced spliced variant of the CYP26B1 gene lacking exon
2. We furthermore investigate the expression of the spliced variant
in vascular cells and in atherosclerotic lesions.
Results and Discussion
Cloning and Expression of a Splice Variant of CYP26B1
Amplification of cDNA from atRA-treated human aortic
smooth muscle cells did not only amplify wild type CYP26B1 but
also a shorter spliced variant. Both variants of the CYP26B1 gene
were cloned into the pZErO vector and sequence analysis revealed
that exon2 (nt 205–429) was missing in the spliced variant (Fig. 1).
To further investigate whether the CYP26B1 spliced variant is
expressed in vascular cells and in normal kidney arteries, PCR was
performed using primers annealing to exon1 and exon 3 of
CYP26B1. The expected PCR products will be 438 bp in the
presence of exon 2, but only 213 bp in its absence. We found that
both the full length and the spliced CYP26B1 were expressed in
HUVECs (Fig. 2A), AOSMCs (Fig. 2B) and normal kidney
arteries (Fig. 2C). Furthermore, the results show that atRA
induced the expression of both CYP26B1 transcript variants in
HUVECs and AOSMCs (Fig. 2A and 2B). To quantify the levels
Figure 1. Amino acid sequence of the splice variant CYP26B1.Alignment of full length and spliced CYP26B1 reveals the exclusion of sequence
corresponding to exon2 in the latter protein.
doi:10.1371/journal.pone.0036839.g001
CYP26B1 Splice Variant and atRA
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real time PCR with specific primers and probes detecting only the
full length or only the spliced CYP26B1. The transcript levels of full
length and the spliced variant of CYP26B1 was 2.5- and 4.5-fold
higher, respectively, in the atherosclerotic lesion compared to
normal arteries (Fig 2D). To investigate if atRA could induce the
spliced variant in atherosclerotic lesions, we treated atherosclerotic
lesions in vitro with 1mM atRA. As seen in Fig. 2D (right panel),
atRA induced the spliced variant 20-fold. In previous experiments
we found that atRA induced the CYP26B1 full length 7-fold in the
atherosclerotic lesions [4]. The corresponding protein expression
of full length and spliced CYP26B1 variants, with predicted sizes
of 57.5 and 50.2 kDa, respectively, were analyzed with western
blot of protein extracts from HUVECs and AOSMCs treated with
atRA or DMSO for 48 hours (Fig. 3A1 and 3A2, lane 1 and 2).
CYP26B1 splice and full length over-expressed in transfected
COS-1 cells was used as positive controls (Fig. 3A, lane 3 and 4
and Fig. 3A2, lane 4 and 3 respectively). It is obvious that
expression of both the full length and the spliced CYP26B1 is
considerably higher in atRA-treated cells than in controls (Fig. 3A1
and 3A2, lane 1 and 2).
Metabolic Activity of CYP26B1 Splice Variant
The activity of the spliced CYP26B1 was determined by
transfecting COS-1 cells with either full length or spliced
CYP26B1 expression constructs, a combination of both, or the
corresponding empty vector pcDNA3.2/V5-DEST, together with
RARE-SEAP and control luciferase vectors. The results show that
the CYP26B1 full length version reduced the RARE-regulated
SEAP activity in comparison with cells transfected with the empty
vector. Surprisingly, in cells transfected with the spliced variant the
SEAP activity was almost the same as in cells transfected with
empty vector (Fig. 3B). This implies that the full length CYP26B1
catabolises atRA, resulting in reduced RAR-mediated signaling,
which is in agreement with previous studies [25], whereas the
spliced CYP26B1 has little or no impact on atRA catabolism. In
cells, transfected with a combination of both spliced and full length
CYP26B1 (Fig. 3B), the SEAP activity was higher compared with
cells transfected with full length CYP26B1 alone.
To further investigate whether the capacity to metabolise RA
differs between the full length and spliced variants of CYP26B1,
COS-1 cells were transiently transfected with the two expression
vectors besides the control vector and incubated with [
3H]atRA
for 1 h (Fig. 3C1). The results show, in agreement with the
Figure 2. mRNA Levels for the CYP26B1 Spliced Variant in Vascular Cells and in Normal vessels. CYP26B1 expression in human umbilical
vein endothelial cells (HUVECs), aortic smooth muscle cells (AOSMCs) and normal kidney arteries. PCR was performed using primers annealing to
exon 1 and exon 3 of CYP26B1. In the presence of exon 2 the expected PCR products is 438 bp, in its absence only 213 bp. (A) HUVEC, (B) AOSMC, (C)
three independent samples of normal kidney arteries, (D) quantitative RT-PCR analysis of CYP26B1 transcript levels in atherosclerotic lesion (n=6) and
normal kidney arteries (n=5) and transcript levels of CYP26B1 splice variant in atherosclerotic lesion treated with DMSO (n=4) and atRA (n=4) (right
panel).
doi:10.1371/journal.pone.0036839.g002
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decreased the cellular levels of atRA compared with cells
transfected with empty vector (Fig. 3C1). Interestingly, cells
transfected with the spliced variant of CYP26B1 showed an
increase in cell-associated [
3H]atRA compared to cells transfected
with full length CYP26B1 and empty vector (Fig. 3C1). This
indicates that the spliced variant interferes with endogenous
enzymes that catabolise atRA in COS-1 cells, reducing the rate of
atRA catabolism. To further explore whether this is a general
phenomenon, THP-1 cells that catabolise atRA at a lower rate
than COS-1 cells were transfected with the different plasmid
constructs. In contrast to COS-1 cells, an increased degradation of
atRA by the CYP26B1 splice variant, compared with empty vector
alone, was seen (Fig. 3C2). Taken together, this result indicates
that the CYP26B1 splice variant could increase or decrease the
catabolism of atRA depending on the levels of other atRA
catabolizing enzymes in the cells.
To investigate the effect of different levels of CYP26B1 variants,
we transfected COS-1 cells with different concentrations of
plasmid construct. As seen in Fig. 3D, transfection with 0.1mg-
1 mg of the CYP2B1 full length showed a concentration dependent
decrease of atRA levels. In contrast, transfection of the cells with
CYP26B1 spliced variant showed a concentration dependent
increase of atRA. Transfection of the cells with a mix of CYP26B1
variants in different concentrations, half amount of CYP26B1
spliced variant plasmid (ratio1:2) was needed to partly inhibit the
increased degradation seen after transfection with full length
CYP26B1.
To further investigate the function of the full length and spliced
variants of CYP26B1, affinity purified proteins were incubated with
25 and 100 nM [
3H]atRA for different intervals or with different
concentrations of atRA for 5 minutes (Fig. 4A-B). The assay shows
that the spliced variant of CYP26B1 retained the capability of
atRA degradation (Fig. 4A-B), but at a rate that is approximately
one-third of the full length enzyme during the first minute,
whereafter the rate was almost similar as for the full length
enzyme. The large difference in catalytic rate between the full-
length and spliced CYP26B1 at the start of the experiment (i.e. at
Figure 3. Protein expression of the CYP26B1 splice variant in HUVEC, AOSMCs and COS-1 cells. (A1) Expression of full length and spliced
CYP26B1 in atRA-treated human umbilical vein endothelial cells (HUVECs) and (A2) aortic smooth muscle cells (AOSMCs) treated with atRA (lane 1)
and DMSO (lane 2) and COS-1 cells transfected with constructs for spliced variant (A1, lane 3, and A2, lane 4) and full length CYP26B1 (A1, lane 4, and
A2, lane 3), detected with Western blot analysis. (B) Cell-based reporter pRARE-TA-SEAP was used to measure retinoid levels in the presence of the full
length and spliced CYP26B1 in COS-1 cells. SEAP: luciferase ratio in COS-1 cells transfected with either of the two different CYP26B1 variants, both
variants simultaneously, or empty vector after 24 hours treatment with either atRA or DMSO (control). (C1) Cellular concentration of exogenously
added [
3H] atRA in COS-1 and (C2) THP-1 cells transfected with either of the two different CYP26B1 variants or empty vector. (D4) COS-1 cells
transfected with different concentrations of the CYP26B1 variants separately or in combination. The values are expressed as mean 6 S.D., n=4.
Statistical significance between CYP26B1 variants was analysed by Student’s t test and ANOVA, *P,0.05,**P,0.01, ***P,0.001 (spliced variant vs.
CYP26B1 full length).
doi:10.1371/journal.pone.0036839.g003
CYP26B1 Splice Variant and atRA
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considerably higher Km for the splice variant or a possible
difference in regulation by atRA and its reaction products caused
by the deletion.
Moreover, incubating a combination of both variants with
100 nM of [
3H]atRA for 10 minutes or 25nM of [
3H]atRA for
different intervals, decreased catabolism of atRA compared with
the full length enzyme alone (Fig. 4C and D). Our results indicate
that the spliced variant possesses a similar affinity for atRA as the
full length protein but catabolises it at only one-third of the rate of
the full length protein.
Conclusion
In the present study, we have cloned and characterised a spliced
variant of the CYP26B1 gene which is atRA-inducible in vascular
cells. The splice variant shows a slower and reduced degradation
of atRA as compared with the full length CYP26B1. One could
speculate that the function of the spliced variant may be to reduce
available atRA at a lower rate than full length CYP26B1, thereby
regulating the rate of atRA degradation. This would prevent a
complete depletion of atRA in the cell after induction of CYP26B1.
Our results also suggest that the effects of the CYP26B1 spliced
variant are highly dependent on its relative concentration
compared to that of other atRA catabolising enzymes, although
its interaction with other co-factors and/or retinoid-binding
proteins is yet unknown. Further studies, however, are needed to
clarify the substrate specificity and the role of the CYP26B1 splice
variant in health and disease.
Materials and Methods
Human Biopsies, Tissue Culture, Cell Culture and cDNA
Synthesis
Ten patients with atherosclerosis scheduled for carotid endar-
terectomy and five patients without history of cardiovascular
disease scheduled for nephrectomy were included [27]. Six
atherosclerotic lesions and five renal arteries were snap-frozen.
Four lesions were divided in two and incubated in DMEM/F12
enriched with 30 mg/mL of human albumin (Biovitrum AB,
Stockholm, Sweden) for 6 h with 1 mM atRA (Sigma-Aldrich, St.
Louis, MO, USA) or vehicle (DMSO). These studies were
Figure 4. Enzymatic and metabolic assay of CYP26B1. (A) CYP26B1 full length and splice variant were incubated with 25 nM and 100 nM of
[
3H] atRA, respectively, for different time points as indicated. (B) CYP26B1 full length or splice variant was incubated with different concentrationso f
[
3H] atRA for 5 minutes and the disappearance of [
3H] atRA was followed. (C&D) CYP26B1 full length, splice variant, combination of both, and control,
incubated with 100 nM of [
3H] atRA for 10 minutes(C) or incubated with 25nM of [
3H] atRA for different time points (D) as indicated in figure. The
control used in the experiment was either full length CYP26B1 or spliced variant CYP26B1 without initiation by NADPH, the values in the figures are
mean 6SD, n=3analyzed by Student’s t-test (Fig4 A &B) and ANOVA (Fig 4C&D),*P,0.05, **P,0.01, ***P,0.001 vs. CYP26B1 full length.
doi:10.1371/journal.pone.0036839.g004
CYP26B1 Splice Variant and atRA
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subjects were included after informed consent.
Human aortic smooth muscle cells (AOSMCs) and human
umbilical vein endothelial cells (HUVECs) were purchased from
Cambrex BioScience (Walkersville, Maryland MD, USA) and
maintained in recommended growth medium (Cambrex BioSci-
ence). HUVECs and AOSMCs at passage 5 to 10 were used
throughout the whole study. Confluent AOSMCs and HUVECs
cultured in 6-well plates were exposed to 1mM atRA or the vehicle
(DMSO) for different time periods.
Total RNA was isolated using the E.Z.N.A., total RNA kit
(Omega Bio-Tek, Doraville, GA, USA) according to the manu-
facturer’s protocol. Finally, 1mg RNA was reverse-transcribed to
cDNA using random hexamers and Superscript II reverse
transcriptase (Invitrogen, Stockholm, Sweden).
Cloning and Sequencing of the CYP26B1 Spliced Variant
CYP26B1 was amplified from cDNA synthesized from atRA-
treated human AOSMCs. The PCR reaction was carried out with
Takara Ex Taq polymerase (Takara Bio Europe, Saint-Germain-
en-laye, France) and CYP26B1 specific primers tagged with
recognition sequences for the restriction enzyme BsrGI: forward
primer (59- ATG CCA ACT TTG TAC AAA AAA GCA GGC
ACC ATG CTC TTT GAG GGC TTG GAT CTG GT-39), and
reverse primer (59- TGC CAA CTT TGT ACA AGA AAG CTG
GGT TCT AGA CTG TGG CGC TCA GCAT-39) (Sigma-
Aldrich, St.Louis, MO, USA). The PCR conditions were as
follows; 94uC for 2 minutes, followed by 35 cycles at 94uC for 45
seconds, 55uC for 60 seconds, and 72uC for 2 minutes. The PCR
products were cloned into the pZErO vector (Invitrogen) and the
constructs were sequenced using an ABI PRISM
TM 310 Gene
Analyzer (Applied Biosystems, Foster City, CA, USA). Both
CYP26B1 (full length accession number ‘‘NP063938’’ and splice
variant accession number ‘‘FJ467289’’ were sequenced and
analysed by using the Lasergene software (DNASTAR Inc,
Madison, WI. USA).
CYP26B1 was sub-cloned into the pcDNA3.2/V5-DEST vector
(Invitrogen) and amplified by PCR using the same primers and
PCR conditions as described above for the cloning into the pZErO
vector. The pZErO plasmid containing the CYP26B1 spliced gene
was used as template. The integrity of the final pcDNA3.2/V-5
DEST-CYP26B1 spliced construct was confirmed by sequence
analysis. CYP26B1 full length cDNA was recombined with
pcDNA3.2/V5-DEST Vector according to the protocol provided
by the manufacturer using Gateway
R LR Clonase
TM II enzyme
mix (Invitrogen).
CYP26B1 Gene Expression
PCR was performed to determine if the CYP26B1 spliced
variant was expressed in AOSMCs, HUVECs and normal vessels.
The forward primer (59-CAC TCG CGA CAA GAG CTG-39)
was located on exon 1 and the reverse primer (59-GCC TCC
TGG TAC ACG TTG AT-39) on exon 3 (Sigma-Aldrich). The
cDNA from normal vessels and atRA- and DMSO-treated
AOSMCs and HUVECs were used as the template and AmpliTaq
Gold DNA polymerase (Applied Biosystems) was used for
amplification. The PCR reaction was initiated at 94uC for 5 min
followed by 35 cycles at 95uC for 45s, 57uC for 45s and 72uC for 2
minutes. PCR products were resolved in a 1% agarose gel
containing ethidium bromide and the amplicons were monitored
under UV-light.
Quantitative Analysis of CYP26B1mRNA Levels by Real
Time PCR
The mRNA levels were determined by using real-time
quantitative polymerase chain reaction using TaqMan universal
PCR master mix, Assay on demand
TM (Applied Biosystems,) for
the full-length CYP26B1. Primers and probe of the CYP26B1
spliced variant was designed and obtained from Sigma. The PCR
analysis was performed using a 7900HT Fast Real-Time PCR
System (Applied Biosystems according to the manufacturer’s
instructions). The results were normalized using Cyclophilin A
(Hs04194521) (Applied Biosystems) as a reference gene.
Transient Transfection of COS-1 and THP-1 Cells with the
CYP26B1 Spliced Variant
COS-1 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) 1X (Invitrogen) supplemented with 10% FBS,
2mM L-glutamine and 0.1% penicillin-streptomycin solution in a
humidified atmosphere (5% CO2, 95% air, 37uC) until they
reached 75–85% confluence. Cells were trypsinized and seeded
into 6-well plates at 3.2610
5 cells/well in DMEM containing 10%
FBS and 2mM L-glutamine without antibiotics for 24 hours prior
to transfection. COS-1 cells were transfected in duplicates with
2mg plasmid DNA/well of either the CYP26B1 full length
construct, the CYP26B1 spliced construct or empty pcDNA3.2/
V5-DEST vector using 6ml of Lipofectamin 2000 (Invitrogen)
diluted in 200ml of DMEM without supplements. To investigate
the effect of different levels of CYP26B1 variants, COS-1 cells were
transfected with different concentrations and combinations of the
full-length CYP26B1, or spliced variant construct or empty vector,
with a final plasmid DNA concentration 1 mg.
For THP-1 cells, the cells were seeded in 12 wells plates at
density of 1610
6 cells/well followed by differentiation with 20 nM
PMA for 24 h. The next day, cells were transfected with 1 mgo f
either CYP26B1 construct or pcDNA3.2/V5-DEST vector without
insert using 2 ml of Turbofect (Fermentas, Leon-Rot, Germany).
In a second set of experiments, COS-1 cells were plated at
8610
4cells/well in 24-well plates, transfected with 50ng each of
pTA-RARE-SEAP (Roche Diagnostics Scandinavia AB, Stock-
holm, Sweden) and pSG5-RARa constructs; 15ng of pMetLuc-
Control (Invitro Sweden AB, Stockholm, Sweden) and 25 ng of
pcDNA3.2/V5-DEST-CYP26B1 (spliced or full length ) or empty
pcDNA3.2/V5-DEST, using 1.5mL of Lipofectamine 2000. After
transfection, cells were incubated for 24 hours at 37uC with 5%
CO2. Transfected cells were exposed to 1mM atRA or DMSO for
24 hours. The media were collected for analysis of secreted
alkaline phosphatase (SEAP) activity after 24 hours incubation.
The SEAP activity was measured using the SEAP Reporter gene
Assay Chemiluminescence according to the manufacturer’s
instruction (Roche AB). Secreted luciferase activity was measured
using Ready-to-Glow
TM Secreted Luciferase Reporter Assay kit
Clontech (Invitro Sweden AB).
Analysis of Retinoic Acid Metabolism in COS-1and THP-1
Cells by HPLC
COS-1 and THP1 cells were transfected for 24 hours with
pcDNA3.2/V5-DEST-CYP26B1full length/spliced constructs and
pcDNA3.2/V5-DEST empty vector as described above. The cells
in each well were supplemented with 1 ml fresh DMEM
containing 1mCi [
3H]atRA (PerkinElmer Life Sciences, Boston,
MA, USA). Following incubation with atRA for 1h the medium
was removed, cells were washed once with ice-cold PBS containing
1mg/ml of bovine serum albumin, twice with ice-cold PBS
without albumin and frozen at -20uC. Cell-associated radioactivity
CYP26B1 Splice Variant and atRA
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content was separated by reversed-phase HPLC after hydrolysing
the samples in 500 ml ethanol and 100 ml of 80% KOH followed
by extraction of [
3H]atRA with n-hexane. The extract was
evaporated and dissolved in methanol, and subsequently separated
on a 5-mm ODS column using a mobile phase containing
acetonitrile/water/acetic acid (80:20:0.05) at a flow rate of
0.8 mL/min. The eluate was mixed 1:3 (vol/vol) with Optima
Flow AP scintillation liquid and the radioactivity was measured
online using a Radiometric 525 TR monitor (Canberra Packard).
All experiments were conducted in a light-restricted regimen.
Affinity Purification of CYP26B1
CYP26B1 was affinity purified from COS-1 cells transfected
with the full length or spliced variant and from HUVEC and
AOSMCs cells treated with 1mM of atRA for 48 hours, using
mouse anti-human monoclonal CYP26B1 antibodies (Abnova,
Taipei City, Taiwan) and the IP pierce kit (Fischer Scientific,
Go ¨teborg, Sweden) following the instruction from the company.
Purified CYP26B1 full length and spliced variant were stored in a
buffer (50mM KH2PO4, 50mM K2HPO4, 0.5 mM EDTA and
20% glycerol, pH 7.4) at -80uC.
CYP26B1 Enzymatic Activity Assay
CYP26B1 assay was performed as follows: 5 nM of either full
length or spliced CYP26B1, 10 nM oxidoreductase (Electra-Box
Diagnostica AB, Tyreso ¨, Sweden), 25nM [
3H]atRA and 1 mM of
NADPH were mixed. The total volume of the reaction was
adjusted to 100ml with 100 mM pH 7.4 potassium phosphate
buffer (KPi buffer). The mixtures were incubated at 37uC for
different times. The reactions were stopped by addition of 500 ml
99.5% ethanol followed by HPLC analysis as described above.
The control used in the experiment was either the full length or
spliced CYP26B1 without the addition of NADPH.
Western Blot Analysis
Western blot was performed as previously described [28] using
mouse anti- human CYP26B1 monoclonal antibodies (Abnova,
Taipei City, Taiwan) at 1:1000 dilution and horseradish-peroxi-
dase-conjugated secondary antibodies anti-mouse 1:1000 dilution,
both dissolved in 3% non-fat dry milk (GE Healthcare, Uppsala,
Sweden) in TBS. Peroxidase activity was detected using the ECL
detection kit (GE Healthcare) and recorded on HyperFilm
TMMP
(GE Healthcare).
Statistical Analysis
All data are presented as mean 6 S.D., and comparisons
between groups were analysed by paired Student’s t-test and one
way ANOVA for comparing more than two groups. P,0.05 was
considered as statistically significant.
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